Latest news
-
SHS Capital acquires majority stake in Basic Pharma
Dutch CDMO Basic Pharma announced that German investment firm SHS Capital has acquired a majority stake in the company, with the investment expected to support additional manufacturing capacity. The announcement highlights Basic Pharma’s development and… [Read more . . .]
-
VaxDome partners with Matica Bio on development of intranasal antiviral / vaccine
According to Texas-based CDMO Matica Biotechnology, the company will provide development and manufacturing services to vaccine developer VaxDome, also based in Texas, to advance a VaxDome intranasal antiviral / vaccine candidate into clinical trials. Matica… [Read more . . .]
-
Sino Biopharm licenses TQC3721 inhaled PDE3/4 inhibitor to AstraZeneca, licenses Trelegy Ellipta and Anoro Ellipta from GSK
According to Sino Biopharmaceutical, AstraZeneca will pay $200 million up front and a total of up to $1.9 billion for the development, manufacturing, and commercialization rights to Sino Biopharm’s TQC3721 inhaled PDE3/4 inhibitor outside of… [Read more . . .]
-
ARS Pharma names Donn Casale as its new CEO
ARS Pharmaceuticals, whose only product is neffy epinephrine nasal spray, announced that long-time CEO Richard Lowenthal has left the company and that Donn Casale, has taken over as CEO and Director. Casale joined ARS Pharma… [Read more . . .]
-
Nebu-Flow joins Innovate UK Scaleup Programme
Nebulizer developer Nebu-Flow, which recently received a £2 million Scottish Enterprise grant, announced that it has been invited to join the Innovate UK Scaleup Programme, which will provide access to a “virtual executive team.” The… [Read more . . .]
Other recent news
-
Atisama and Monash University get AU $15 million for continued development of RB042 inhaled SSO therapy
-
Vistagen says Phase 3 PALISADE-4 study of fasedienol nasal spray for social anxiety disorder failed to meet its primary endpoint
-
Insmed names Samuele Butera as Senior VP, General Manager, Global Respiratory
-
Zymeworks to acquire Theravance Biopharma and its Yupelri revefenacin inhalation solution
-
Leyden Labs gets €40 million in financing for continued development of PanFlu antiviral nasal spray
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
